Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q3 FY24 results · Oct–Dec 2023

Jubilant Pharmova reported revenue from operations of ₹1,677.10 crore (up 8.0% from Q3 FY23) and net profit of ₹66.40 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY24	Q3 FY23	YoY	Q2 FY24	QoQ
Revenue from operations	1,677.10	1,552.51	+8.0%	1,680.30	−0.2%
Other income	35.80	9.47	+278.0%	9.90	+261.6%
Total income	1,712.90	1,561.98	+9.7%	1,690.20	+1.3%
Profit before share of associates & JVs and tax	87.90	10.38	+746.8%	89.00	−1.2%
Share of profit/(loss) of associates & JVs	13.10	(1.65)		9.00
Net profit for the period	66.40	(16.04)	Turned profit	62.10	+6.9%
Attributable to shareholders of the company	66.80	(15.67)	Turned profit	62.50	+6.9%
EPS, basic (₹)	4.22	(0.98)	Turned profit	3.94	+7.1%
Net margin (%)	4.0	-1.0		3.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY24	Q3 FY23	YoY	Q2 FY24	QoQ
Revenue from operations	175.20	182.74	−4.1%	186.30	−6.0%
Other income	19.00	7.87	+141.4%	18.40	+3.3%
Total income	194.20	190.61	+1.9%	204.70	−5.1%
Profit before tax	(2.30)	(11.14)	Loss narrowed	0.20	Turned loss
Net profit for the period	(2.40)	(5.89)	Loss narrowed	(0.40)	Loss widened
EPS, basic (₹)	(0.15)	(0.37)	Loss narrowed	(0.03)	Loss widened
Net margin (%)	-1.4	-3.2		-0.2

Consolidated

Filed with BSE: 03 Feb 2024, 15:44 IST
Board meeting: 02 Feb 2024
Period: 01 Oct 2023 to 31 Dec 2023
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 03 Feb 2024, 15:44 IST
Board meeting: 02 Feb 2024
Period: 01 Oct 2023 to 31 Dec 2023
Review status: Unaudited
Source: XBRL filing on BSE